US4826875A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
Assignee: Chiesi Farmaceutici SpA
•
Filing: 1987-11-20
•
Granted: 1989-05-02
•
Expires: 2007-11-20
Abstract
Abstract Pharmaceutical compositions for the treatment of Parkinson's disease and neurologic syndromes connected with it, containing as the active principle Levodopa methyl ester optionally combined with other active principles selected from dopaminergi, anticholinergic, antidepressive drugs, carboxylase and monoaminoxidase inhibitors.
Inventors
- 👤 Paolo Chiesi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 18:23
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K31/21; A61K31/215; A61K31/235; A61K31/24; A61P; A61P25/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
61 words
A pharmaceutical composition for oral and sublingual use which contains per unit dose 100 to 300 mg of levodopa methyl ester (LDME) as one active ingredient and a member selected from the group consisting of benserazide, carbidopa and deprenyl in the ratio respectively of 2:1 to 5:1; 4:1 to 20:1, and 20:1 to 100:1 in the form of tablets or capsules.
Claim 2
Dependent Claim
61 words
A pharmaceutical composition for oral and sublingual use which contains per unit dose 100 to 300 mg of levodopa methyl ester (LDME) as one active ingredient and a member selected from the group consisting of benserazide, carbidopa and deprenyl in the ratio respectively of 2:1 to 5:1; 4:1 to 20:1, and 20:1 to 100:1 in the form of tablets or capsules.
Claim 3
Dependent Claim
21 words
The composition according to claim 1 which contains 100-300 mgs of LDME and benserazide in the ratio between 2:1 and 5:1.
Claim 4
Dependent Claim
21 words
The composition according to claim 1 which contains 100-300 mgs of LDME and carbidopa in the ratio between 4:1 and 10:1.
Claim 5
Dependent Claim
17 words
The composition according to claim 1 which contains 100-300 mgs of LDME and 5 mgs of deprenyl.
Claim 6
Dependent Claim
46 words
A pharmaceutical composition in the form of an aqueous solution which contains levodopa methyl ester in a concentration ranging from 50 to 400 mg/cc. in combination with benserazide, carbidopa or deprenyl in a ratio respectively between between 2:1 and 10:1; 4:1 and 20:1; 20:1 and 100:1.
Claim 7
Dependent Claim
46 words
A pharmaceutical composition in the form of an aqueous solution which contains levodopa methyl ester in a concentration ranging from 50 to 400 mg/cc. in combination with benserazide, carbidopa or deprenyl in a ratio respectively between between 2:1 and 10:1; 4:1 and 20:1; 20:1 and 100:1.
Claim 8
Dependent Claim
22 words
The composition according to claim 5 which contains 50-400 L mg/cc of LDME and benserazide in the ratio of 2:1 and 10:1.
Claim 9
Dependent Claim
21 words
The composition according to claim 5 which contains 50-400 mg/cc. of LDME and carbidopa in the ratio of 4:1 and 20:1.
Claim 10
Dependent Claim
19 words
The composition according to claim 5 which contains 50-400 mg/c. and deprenyl in the ratio of 20:1 and 100:1.
Claim 11
Independent Claim
67 words
The method of treating Parkinson's disease and related neurological syndromes which consists of administering to a living subject in need of treatment a pharmaceutical composition in the form of tablets or capsules containing 100-300 mgs of levodopa methyl ester (LDME) as one active ingredient and at least one member selected from the group consisting of benserazide, carbidopa or deprenyl, in the ratio of 2:1-5:1; 4:1-20:1, and 20:1-100:1.
Claim 12
Independent Claim
67 words
The method of treating Parkinson's disease and related neurological syndromes which consists of administering to a living subject in need of treatment a pharmaceutical composition in the form of tablets or capsules containing 100-300 mgs of levodopa methyl ester (LDME) as one active ingredient and at least one member selected from the group consisting of benserazide, carbidopa or deprenyl, in the ratio of 2:1-5:1; 4:1-20:1, and 20:1-100:1.
Claim 13
Independent Claim
66 words
The method of treating Parkinson's disease and related neurological syndromes which consists of administering to a living subject in need of treatment a pharmaceutical composition in the form of an aqueous solution containing levodopa methyl esfter in a concentration ranging from 50 to 400 mg/cc. in combination with benserazide, carbidopa or deprenyl in a ratio respectively between 2:1 and 10:1; 4:1 and 20:1; 20:1 to 100:1.
Claim 14
Independent Claim
66 words
The method of treating Parkinson's disease and related neurological syndromes which consists of administering to a living subject in need of treatment a pharmaceutical composition in the form of an aqueous solution containing levodopa methyl esfter in a concentration ranging from 50 to 400 mg/cc. in combination with benserazide, carbidopa or deprenyl in a ratio respectively between 2:1 and 10:1; 4:1 and 20:1; 20:1 to 100:1.
References Cited (Backward Citations)
US4663349A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-05-01 | 1992-10-31 | 1993-05-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-05-01 | 1996-10-31 | 1997-05-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-05-01 | 2000-10-31 | 2001-05-02 | $7700.00 | Window Closed / Lapsed |